Novel missense variants in the RNF213 gene from a European family with Moyamoya disease by Gagunashvili, AN et al.
Gagunashvili et al. Human Genome Variation            (2019) 6:35 
https://doi.org/10.1038/s41439-019-0066-6 Human Genome Variation
DATA REPORT Open Ac ce s s
Novel missense variants in the RNF213
gene from a European family with
Moyamoya disease
Andrey N. Gagunashvili1, Louise Ocaka1, Daniel Kelberman1, Pinki Munot2, Chiara Bacchelli1, Philip L. Beales1 and
Vijeya Ganesan2,3
Abstract
In this report, we present a European family with six individuals affected with Moyamoya disease (MMD). We detected
two novel missense variants in the Moyamoya susceptibility gene RNF213, c.12553A>G (p.(Lys4185Glu)) and
c.12562G>A (p.(Ala4188Thr)). Cosegregation of the variants with MMD, as well as a previous report of a variant
affecting the same amino acid residue in unrelated MMD patients, supports the role of RNF213 in the pathogenesis
of MMD.
Moyamoya (MM) is a rare cerebrovascular disorder that
is characterized by a high rate of stroke and frequent
recurrence. When MM is associated with a recognized
genetic or acquired condition, it is termed MM syndrome
(MMS). The majority of cases appear to be idiopathic in
origin and are termed MM disease (MMD). Linkage stu-
dies have identiﬁed a number of loci in reports of cases,
albeit with incomplete penetrance, suggesting a role for
genetic factors in the etiology of MMD. Elucidation of the
genes involved has been hampered by several complicat-
ing factors, including clinical and radiological phenotypic
heterogeneity, incomplete penetrance and variable onset
of the disease. The inheritance pattern in the majority of
cases is unclear. The use of whole-exome sequencing has
allowed for the identiﬁcation of a number of rare variants
in genes linked to rare Mendelian forms, particularly
when associated with a broader spectrum of disease in
patients with MMS. However, in idiopathic cases of
MMD, variations in the RNF213 gene have been identiﬁed
as conferring susceptibility to MMD. In particular, a
founder variant c.14429G>A (p.(Arg4810Lys) (dbSNP
accession rs112735431)) has been observed in 80% of
Japanese and East Asian MMD patients, compared to 2%
in the general population1,2. The diversity of susceptibility
variants in MMD patients of European ancestry remains
underrepresented.
In this report, we analyzed a white European family
from the UK with six relatives affected with MMD over
three generations (Fig. 1a) (for a detailed description of
the clinical presentation, see Supplementary Text S1). In
an attempt to ﬁnd a genetic cause of MMD in this
family, two affected and three unaffected members of
the family (denoted with a plus sign in Fig. 1a) under-
went whole-exome sequencing to an average coverage of
104.6× (range of 98.4–108.5×) such that, on average,
96.2% of the exome capture target regions was covered
by at least 20× (for a detailed description of the methods
see Supplementary Text S2). We focused our analysis on
coding and splice region variants (single nucleotide
variants and indels) that are not present or rare (allele
frequency <0.5%) in public databases of human genetic
variation: ExAC/gnomAD, 1000 Genomes Project and
NHLBI ESP.
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Fig. 1 Novel missense variants in the RNF213 gene from a European family with MMD. a Pedigree of the family. The genotypes of the two
RNF213 variants are shown below each family member for which a DNA sample was available, where red refers to the status of the missense variant
c.12553A>G (p.(Lys4185Glu)), and blue refers to the status of the missense variant c.12562G>A (p.(Ala4188Thr)) (reference allele/alternate allele). Filled
symbols denote affected individuals, unﬁlled symbols denote unaffected individuals, and slashed lines denote deceased. Five individuals who were
whole-exome sequenced are denoted with a plus sign. P, proband. The genotypes of other family members were obtained with Sanger sequencing.
b The domain structure of the RNF213 protein based on14 and variants previously reported in East Asian and European MMD patients1,2,5,11–13,15–20
(shown above and below the protein, respectively). The variants reported for both populations are underlined, and the ones identiﬁed in this study
are shown in blue. Two distinct regions with different missense constraints identiﬁed by Samocha and coworkers6 are shown below the protein.
c Conservation of amino acid residues affected by the c.12553A>G (p.(Lys4185Glu)) and c.12562G>A (p.(Ala4188Thr)) variants. AAA+, ATPases
associated with various cellular activity domains; RING, RING-ﬁnger domain
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Analysis of ﬁltered genetic variants was performed
assuming a dominant mode of inheritance. X-linkage
could not be excluded due to the absence of any male-to-
male transmission within the pedigree. However, there is
at least one instance of nonpenetrance in the family as
individual II:8, although clinically unaffected, is an obli-
gate carrier of the variant(s) that he passed onto his
affected daughter (III:9). Consequently, individual II:8 was
classiﬁed as “affected” for the purpose of the genetic
analysis (for a detailed description of the variant analysis,
see Supplementary Text S3). The observation of incom-
plete penetrance is consistent with other reports of MMD
inheritance3,4.
No potential candidate variants were identiﬁed that
were consistent with an X-linked dominant mode of
inheritance (Supplementary Fig. S2). Analysis of the
autosomes identiﬁed 20 candidate variants, 16 of which
were predicted to be deleterious to protein function
(missense and frameshift variants) (Supplementary Fig.
S2, Supplementary Table S1). Of these sixteen candidates,
two missense variants, c.12553A>G (p.(Lys4185Glu)) and
c.12562G>A (p.(Ala4188Thr)) (Supplementary Table S1),
were identiﬁed in the RNF213 gene, which has previously
been reported as a major susceptibility gene for MMD1,2.
No other candidates were identiﬁed in our analysis that
could explain the disease in the affected family members.
The parental aunt (II:1) and uncle (II:5) of the proband
are both obligate carriers of these variants, both having
affected children (III:1, III:2 and III:7) (Supplementary Fig.
S3 and S4). The clinically unaffected sister of the proband
(III:8) also harbors the variants, further demonstrating the
incomplete penetrance characteristic of the condition
(Supplementary Fig. S3 and S4, Supplementary Table S2).
These individuals are clinically asymptomatic and are
currently undergoing clinical evaluation. Brain imaging
studies have not been undertaken to date.
The variants identiﬁed are currently private to the
family and have not been previously documented or
reported in public databases (Table 1). Both variants
cosegregate with MMD in multiple affected family
members and obligate carriers (Supplementary Fig. S5).
The p.(Lys4185Glu) is a conservative amino acid sub-
stitution that occurs at a position that is conserved across
species (Fig. 1c, Supplementary Table S3). Multiple lines
of computational evidence support a deleterious effect of
the c.12553A>G (p.(Lys4185Glu)) variant on the gene
product (Supplementary Table S3). A heterozygous mis-
sense variant affecting the same lysine residue
(c.12554A>C, p.(Lys4185Thr)) has also been previously
reported in an unrelated family of European ancestry with
MMD5. The c.12554A>C variant also has similar dele-
terious in silico predictions to those for p.(Lys4185Glu)
(Supplementary Table S3). Predictions for the
c.12562G>A (p.(Ala4188Thr)) variant were mostly
benign, suggesting that this variant may have a limited
impact on the resultant protein (Supplementary Table S3).
Genetic studies of familial MMD are complicated by
considerable heterogeneity, incomplete penetrance of the
condition and variable onset of the disease. RNF213 has
been identiﬁed as a major susceptibility gene for MMD,
mostly in cases of East Asian ancestry. Interestingly, both
East Asian and European MMD patients show very little
overlap in RNF213 variants associated with the disease
(Fig. 1b). Apart from the founder variant c.14429G>A (p.
(Arg4810Lys))2, the differences between East Asian and
European MMD-associated variants can be explained by a
spread of spontaneously arisen mutations.
According to the gnomAD database, RNF213 is an
unconstrained gene with a high tolerance to both mis-
sense (2527 observed vs. 2920 expected, z-score: 2.64) and
loss-of-function (124 observed vs. 221.8 expected, pLI-
score: 0) variants. Nevertheless, there are no homozygous
loss-of-function RNF213 variants in gnomAD (accessed
on January 2019), suggesting that complete loss of the
RNF213 gene would not be tolerated. In contrast, highly
constrained genes harboring variants that result in
Table 1 Summary of the RNF213 variants found in the
European family with MMD
Variant 1 Variant 2
Position (GRCh38) chr17:80,372,536 chr17:80,372,545
Variant
consequences
Missense Missense
Variant genotype Heterozygous Heterozygous
cDNA change c.12553A>G
(NM_001256071.2)
c.12562G>A
(NM_001256071.2)
Protein change p.(Lys4185Glu)
(NP_001243000.2)
p.(Ala4188Thr)
(NP_001243000.2)
Transcript length 21,062 bp
(NM_001256071.2)
21,062 bp
(NM_001256071.2)
Protein length 5,207 aa
(NP_001243000.2)
5,207 aa
(NP_001243000.2)
Exon/exons in
transcript
48/68
(NM_001256071.2)
48/68
(NM_001256071.2)
Allele frequency in public databases:
ExAC/gnomAD 0 0
1000 Genomes 0 0
NHLBI ESP 0 0
Presence in dbSNP Not present Not present
Variant classiﬁcation Likely pathogenic Uncertain signiﬁcance
ClinVar accession SCV000839587 SCV000839588
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haploinsufﬁciency are known to cause severe disease6.
This observation can explain the reduced penetrance of
MMD in families carrying rare RNF213 variants and
suggests that other factors, including genetic background,
are required to trigger the development of the disease.
In this case, we identiﬁed two novel missense variants in
the RNF213 gene in a European family with MMD. The
occurrence of two private variants on the same allele 7 bp
apart (Supporting Fig. S3) suggests the possibility that
they have arisen as a result of a single mutational event7. It
has been shown previously that such clustered, multi-
nucleotide mutations can be introduced by the normal
activity of the more error-prone components of the DNA
repair pathway, such as polymerase zeta8. The presence of
an indel or a larger structural variant at the locus was not
evident from the mapped sequencing reads (Supplemen-
tary Fig. S3).
The variants are situated in the C-terminal region of the
RNF213 protein, where the majority of MMD-associated
variants have been reported (Fig. 1b). This region harbors
a domain for a RING-ﬁnger E3 ligase, which is involved in
the ubiquitination of substrates targeted for either pro-
teasomal degradation or signal transduction. Interestingly,
this part of RNF213 represents one of the two distinct
segments (1–3725 and 3726–5207 amino acids) with
different missense constraints identiﬁed by Samocha and
coworkers6 (Fig. 1b). This suggests that missense variants
in this region may have different deleterious effects on the
protein function compared to the variants in the ﬁrst
segment of RNF213. Applying the American College of
Medical Genetics and Genomics and the Association for
Molecular Pathology (ACMG/AMP) guidelines9,10, we
interpreted the p.(Lys4185Glu) variant in the RNF213
gene as likely pathogenic for MMD, acting in a dominant
manner. The p.(Ala4188Thr) variant was interpreted as a
variant of uncertain signiﬁcance with respect to MMD
due to conﬂicting/insufﬁcient evidence (for a detailed
description of the variant interpretation see Supplemen-
tary Text S4). We could not exclude the possibility of a
synergistic effect of having both of these variants in cis to
cause the phenotype. It will be interesting whether other
unrelated MMD patients who carry only one variant will
be found. The study of such cases may not only conﬁrm
the role of the variants in the pathogenesis of MMD but
may also reveal some phenotypic differences between the
carriers. The multiple reported occurrence of individuals
exhibiting reduced penetrance for a particular disease can
complicate genetic studies and make it difﬁcult to draw
ﬁrm conclusions regarding the association of a particular
gene with disease pathogenesis. To overcome this, the
reporting of novel variants associated with diseases such
as MMD is important to greatly facilitate variant inter-
pretation in the future. Multiple recurrences of the same
variant or variants within the same gene (particularly
affecting the same amino acid residue) in unrelated
patients provide increasing supportive evidence for dis-
ease association. Our ﬁndings support and add more
evidence to the importance of alteration of the C-terminal
region of RNF213, including the RING-ﬁnger domain, in
the pathogenesis of MMD. This study also adds important
weight to a growing body of evidence11–13 that variation
in the RNF213 gene also has an important role in disease
susceptibility in European populations.
HGV database
The relevant data from this Data Report are hosted at the Human Genome
Variation Database at https://doi.org/10.6084/m9.ﬁgshare.hgv.2588, https://doi.
org/10.6084/m9.ﬁgshare.hgv.2591.
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